In contrast, dopaminergic agents (e.g., bupropion, L-DOPA) may be more effective in patients with elevated CRP or IL-17 levels, as they target inflammation-related DA deficits (200) Indeed, MDD patients with CRP >2 mg/L show increased ventral striatum-ventromedial prefrontal cortex connectivity following L-DOPA administration, suggesting that DA-enhancing treatments may be particularly beneficial in inflammation-associated depression (197). The gene discussed is CRP; the disease is depressive disorder.